Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SZSE:000661'
s Operating Margin % Range Over the Past 10 Years
Min: 4.14 Med: 35.01 Max: 44.9
Current: 4.14
SZSE:000661's Operating Margin % is ranked worse than 59.23% of 959
companies
in the Drug Manufacturers industry
Industry Median: 7.26
vs SZSE:000661: 4.14
Changchun High-Tech Industry (Group) Co (SZSE:000661) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Changchun High-Tech Industry (Group) Co Operating Margin % Related Terms
Changchun High-Tech Industry (Group) Co Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Changchun High-Tech Industry (Group) Co Operating Margin % Chart
Changchun High-Tech Industry (Group) Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Changchun High-Tech Industry (Group) Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Changchun High-Tech Industry (Group) Co Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Changchun High-Tech Industry (Group) Co's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Changchun High-Tech Industry (Group) Co's Operating Margin % falls into.
Changchun High-Tech Industry (Group) Co Operating Margin % Calculation
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Changchun High-Tech Industry (Group) Co (SZSE:000661) has a Operating Margin % of 13.91% as of Jun. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Changchun High-Tech Industry (Group) Co and its competitors. This is 60% below median its historical median of 35.01. Over the past decade, Changchun High-Tech Industry (Group) Co's Operating Margin % has ranged from 4.14 to 44.90. According to the industry distribution chart, Changchun High-Tech Industry (Group) Co ranks #568 out of 959 companies in the Drug Manufacturers industry, placing it in the top 59.2%.
Is Changchun High-Tech Industry (Group) Co's Operating Margin % too high?
Changchun High-Tech Industry (Group) Co's current Operating Margin % of 13.91% is 60% below median its 10-year median of 35.01. Over the past 10 years, this metric has ranged from a low of 4.14 to a high of 44.90. The Drug Manufacturers industry median Operating Margin % is 7.26. Changchun High-Tech Industry (Group) Co's value of 13.91% is 91.6% above this industry median. Based on the distribution chart, Changchun High-Tech Industry (Group) Co ranks #568 out of 959 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Changchun High-Tech Industry (Group) Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Changchun High-Tech Industry (Group) Co's Operating Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Changchun High-Tech Industry (Group) Co ranks #568 out of 959 companies for Operating Margin %. This places Changchun High-Tech Industry (Group) Co in the lower half of its industry. The industry median Operating Margin % is 7.26. Changchun High-Tech Industry (Group) Co's value of 13.91% is 91.6% above this benchmark. Historically, Changchun High-Tech Industry (Group) Co's own Operating Margin % has ranged from 4.14 to 44.90 over the past decade. While the company's 10-year median is 35.01 vs. the industry median of 7.26, Changchun High-Tech Industry (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.26, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Changchun High-Tech Industry (Group) Co's current Operating Margin % of 13.91% is 91.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Changchun High-Tech Industry (Group) Co and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Changchun High-Tech Industry (Group) Co's current Operating Margin % is 13.91%, which is 60% below median its own 10-year median of 35.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Changchun High-Tech Industry (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Changchun High-Tech Industry (Group) Co (SZSE:000661) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥85.96, compared to a current price of ¥74.76 — trading 13% below its estimated fair value. The current Operating Margin % is 13.91%, which is 60% below median its 10-year median of 35.01 and 91.6% above the Drug Manufacturers industry median of 7.26. Changchun High-Tech Industry (Group) Co's overall GF Score™ is 84/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Changchun High-Tech Industry (Group) Co (SZSE:000661), the current Operating Margin % is 13.91% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Changchun High-Tech Industry (Group) Co (SZSE:000661) Overvalued in 2026?
Based on GuruFocus' analysis, Changchun High-Tech Industry (Group) Co stock appears to be undervalued.
The current stock price of ¥74.76 is trading 13% below its estimated GF Value™ of ¥85.96.
GuruFocus considers Changchun High-Tech Industry (Group) Co to be Modestly Undervalued.
Key valuation signals for SZSE:000661:
Operating Margin %: 13.91% (60% below median its 10-year median of 35.01)
GF Value™: ¥85.96 vs. price of ¥74.76 (13% below fair value)
Industry Position: 91.6% above the Drug Manufacturers median (#568 of 959)
No single metric tells the full story. See the SZSE:000661 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Changchun High-Tech Industry (Group) Co Ltd is engaged in the production and sales of biopharmaceuticals, Chinese patent medicine production, and real estate development. The company operates its business through three segments. The Pharmaceuticals segment focuses on the research and development, manufacturing, and sales of genetically engineered biologics, human vaccines, traditional Chinese medicines, and chemical pharmaceuticals. The Real Estate segment is involved in property development and sales. The Services segment provides scientific research and technical support, along with leasing and various business-related services. It generates the majority of its revenue from the Pharmaceuticals segment.
84GF Score
Get the complete analysis for SZSE:000661
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:000661 has been successfully added to your 
